Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 3/20 | 0.89 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL362816 | 1.00 | CA4 (0.89) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL18131942 | 1.00 | CA4 (0.89) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL30350220 | 0.97 | CA4 (0.94) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL32679845 | 0.97 | CA4 (0.84) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL2335912 | 0.97 | CA4 (0.84) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL31633755 | 0.97 | CA4 (0.84) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL31413937 | 0.97 | CA4 (0.84) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL22686437 | 0.97 | CA4 (0.94) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL29587574 | 0.97 | CA4 (0.94) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL1291555 | 0.97 | CA4 (0.94) | CA4ALDH1A1CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021137780-A1 | PREPARATION OF FILM TABLET COMPOSITION COMPRISING HEME IRON FOR IRON DEFICIENCY | İLKO İLAÇ SANAYİ VE TİCARET A.Ş. (TR) | 2021-07-08 | — | — | WO | claimed |
| US-9913806-B2 | Patches and methods for the transdermal delivery of a therapeutically effective amount of iron | FE3 MEDICAL, INC. (US) | 2018-03-13 | — | — | US | claimed |
| US-9731982-B2 | Surface modified ceramic filter | UNIVERSITY OF KANSAS (US) | 2017-08-15 | — | — | US | claimed |
| EP-3103510-A1 | SYSTEM FOR TRANSDERMAL IONTOPHORETIC DELIVERY OF CHELATED AGENTS | Incube Labs, Llc (US) | 2016-12-14 | — | — | EP | claimed |
| EP-2320885-B1 | PATCHES FOR THE TRANSDERMAL DELIVERY OF A THERAPEUTICALLY EFFECTIVE AMOUNT OF IRON | FE3 MEDICAL INC (US) | 2016-10-19 | — | — | EP | claimed |
| EP-2421601-B1 | SYSTEM FOR TRANSDERMAL IONTOPHORETIC DELIVERY OF CHELATED AGENTS | INCUBE LABS LLC (US) | 2016-06-15 | — | — | EP | claimed |
| US-20130341281-A1 | Surface Modified Ceramic Filter | UNIVERSITY OF KANSAS (US) | 2013-12-26 | — | — | US | claimed |
| WO-2013075018-A1 | SURFACE MODIFIED CERAMIC FILTER | UNIVERSITY OF KANSAS (US) | 2013-05-23 | — | — | WO | claimed |
| WO-2012092305-A2 | NANONIZED IRON COMPOSITIONS AND METHODS OF USE THEREOF | INCUBE LABS, LLC (US) | 2012-07-05 | — | — | WO | claimed |
| EP-2421601-A2 | METHOD FOR TRANSDERMAL IONTOPHORETIC DELIVERY OF CHELATED AGENTS | Incube Labs, Llc (US) | 2012-02-29 | — | — | EP | claimed |
| WO-2010123584-A2 | METHOD FOR TRANSDERMAL IONTOPHORETIC DELIVERY OF CHELATED AGENTS | INCUBE LABS, LLC (US) | 2010-10-28 | — | — | WO | claimed |
| US-20090035385-A1 | COMPOSITIONS INCLUDING IRON | DRUGTECH CORPORATION (US) | 2009-02-05 | — | — | US | claimed |
| EP-1827418-A2 | COMPOSITIONS INCLUDING IRON | Drugtech Corporation (US) | 2007-09-05 | — | — | EP | claimed |
| EP-1827419-A2 | METHODS AND COMPOSITIONS FOR ENHANCING IRON ABSORPTION | Drugtech Corporation (US) | 2007-09-05 | — | — | EP | claimed |
| WO-2006068697-A2 | COMPOSITIONS INCLUDING IRON | DRUGTECH CORPORATION (US) | 2006-06-29 | — | — | WO | claimed |
| WO-2006068729-A2 | METHODS AND COMPOSITIONS FOR ENHANCING IRON ABSORPTION | DRUGTECH CORPORATION (US) | 2006-06-29 | — | — | WO | claimed |
| US-20060134227-A1 | Compositions including iron | DRUGTECH CORPORATION | 2006-06-22 | — | — | US | claimed |
| WO-2003086321-A2 | MODIFIED RELEASE MINERALS | DRUGTECH CORPORATION (US) | 2003-10-23 | — | — | WO | claimed |
| US-20030190355-A1 | Modified release minerals | DRUGTECH CORPORATION | 2003-10-09 | — | — | US | claimed |
| US-12016906-B2 | Pharmaceutical composition for anaemia | FRIMLINE PRIVATE LIMITED (IN) | 2024-06-25 | — | — | US | disclosed |
| US-11969398-B2 | Methods, compositions, and devices for making sustained biodegradable implants in tissue | PATHAK HOLDINGS LLC (US) | 2024-04-30 | — | — | US | disclosed |
| CN-116636620-A | Black egg white peptide composition and application thereof | 南昌大学 | 2023-08-25 | — | — | CN | disclosed |
| WO-2023119230-A1 | COAGULATION PATHWAY AND NICOTINAMIDE-ADENINE DINUCLEOTIDE PATHWAY MODULATING COMPOSITIONS AND METHODS OF THEIR USE | L'OREAL (FR) | 2023-06-29 | — | — | WO | disclosed |
| EP-3661373-B1 | A PHARMACEUTICAL COMPOSITION FOR ANAEMIA | FRIMLINE PRIVATE LTD (IN) | 2022-06-22 | — | — | EP | disclosed |
| US-20220160830-A1 | COMPOSITIONS COMPRISING CHOLINE | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2022-05-26 | — | — | US | disclosed |
| US-20210275472-A1 | METHODS, COMPOSITIONS, AND DEVICES FOR DRUG / LIVE CELL MICROARRAYS | PATHAK HOLDINGS LLC | 2021-09-09 | — | — | US | disclosed |
| WO-2021137780-A1 | PREPARATION OF FILM TABLET COMPOSITION COMPRISING HEME IRON FOR IRON DEFICIENCY | İLKO İLAÇ SANAYİ VE TİCARET A.Ş. (TR) | 2021-07-08 | — | — | WO | disclosed |
| US-11045433-B2 | Method of making an in situ sustained biodegradable drug delivery implant by filling an artificial tissue cavity | PATHAK HOLDINGS LLC (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200405822-A1 | A PHARMACEUTICAL COMPOSITION FOR ANAEMIA | FRIMLINE PRIVATE LIMITED (IN) | 2020-12-31 | — | — | US | disclosed |
| US-20200230081-A1 | METHODS, COMPOSITIONS, AND DEVICES FOR DRUG / LIVE CELL MICROARRAYS | PATHAK HOLDINGS LLC | 2020-07-23 | — | — | US | disclosed |
| EP-3661373-A1 | A PHARMACEUTICAL COMPOSITION FOR ANAEMIA | Frimline Private Limited (IN) | 2020-06-10 | — | — | EP | disclosed |
| US-10624865-B2 | Methods, compositions, and devices for drug/live cell microarrays | PATHAK HOLDINGS LLC (US) | 2020-04-21 | — | — | US | disclosed |
| US-10463629-B2 | Patches and methods for the transdermal delivery of a therapeutically effective amount of iron | FE3 MEDICAL, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| WO-2019171236-A1 | A PHARMACEUTICAL COMPOSITION FOR ANAEMIA | FRIMLINE PRIVATE LIMITED (IN) | 2019-09-12 | — | — | WO | disclosed |
| US-20190125828-A1 | COMPOSITIONS COMPRISING CHOLINE | JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT | 2019-05-02 | — | — | US | disclosed |
| US-20190046479-A1 | METHODS, COMPOSITIONS, AND DEVICES FOR DRUG / LIVE CELL MICROARRAYS | PATHAK HOLDINGS LLC | 2019-02-14 | — | — | US | disclosed |
| EP-3432870-A1 | COMPOSITIONS COMPRISING CHOLINE | Balchem Corporation (US) | 2019-01-30 | — | — | EP | disclosed |
| EP-2709714-B1 | APPARATUS FOR HEATING A TREATMENT REGION WITH AN ALTERNATING ELECTRIC FIELD | INNOVOLINK LLC (US) | 2019-01-16 | — | — | EP | disclosed |
| US-20180333367-A1 | Patches and Methods for the Transdermal Delivery of a Therapeutically Effective Amount of Iron | FE2, INC. | 2018-11-22 | — | — | US | disclosed |
| US-9956028-B2 | Apparatus and method for heating biological targets | INNOVOLINK, LLC (US) | 2018-05-01 | — | — | US | disclosed |
| US-9913806-B2 | Patches and methods for the transdermal delivery of a therapeutically effective amount of iron | FE3 MEDICAL, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| US-9901742-B2 | Apparatus and method for heating a treatment region with an alternating electric field | INNOVOLINK, LLC (US) | 2018-02-27 | — | — | US | disclosed |
| US-9901387-B2 | Apparatus and method for heating adipose cells | INNOVOLINK, LLC (US) | 2018-02-27 | — | — | US | disclosed |
| WO-2018017674-A1 | METHODS, COMPOSITIONS, AND DEVICES FOR DRUG / LIVE CELL MICROARRAYS | PATHAK HOLDINGS, LLC (US) | 2018-01-25 | — | — | WO | disclosed |
| WO-2017165287-A1 | COMPOSITIONS COMPRISING CHOLINE | BALCHEM CORPORATION (US) | 2017-09-28 | — | — | WO | disclosed |
| US-9731982-B2 | Surface modified ceramic filter | UNIVERSITY OF KANSAS (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170189447-A1 | FORMULATION FOR INCREASING ENERGY | NIS Clinical Research (US) | 2017-07-06 | — | — | US | disclosed |
| US-9675814-B2 | Apparatus and method for obtaining a substantially constant current across a treatment region | INNOVOLINK, LLC (US) | 2017-06-13 | — | — | US | disclosed |
| US-9670080-B2 | Composition and method for treating oilfield water | BAKER HUGHES INCORPORATED (US) | 2017-06-06 | — | — | US | disclosed |
| EP-3103510-A1 | SYSTEM FOR TRANSDERMAL IONTOPHORETIC DELIVERY OF CHELATED AGENTS | Incube Labs, Llc (US) | 2016-12-14 | — | — | EP | disclosed |
| EP-2320885-B1 | PATCHES FOR THE TRANSDERMAL DELIVERY OF A THERAPEUTICALLY EFFECTIVE AMOUNT OF IRON | FE3 MEDICAL INC (US) | 2016-10-19 | — | — | EP | disclosed |
| EP-2421601-B1 | SYSTEM FOR TRANSDERMAL IONTOPHORETIC DELIVERY OF CHELATED AGENTS | INCUBE LABS LLC (US) | 2016-06-15 | — | — | EP | disclosed |
| US-20160022631-A1 | Methods and Compositions for Enhancing Iron Absorption | LUMARA HEALTH IP LTD (US) | 2016-01-28 | — | — | US | disclosed |
| US-20150258035-A1 | Patches and Methods for the Transdermal Delivery of a Therapeutically Effective Amount of Iron | FE2, INC. | 2015-09-17 | — | — | US | disclosed |
| US-8996104-B2 | Patches and method for the transdermal delivery of a therapeutically effective amount of iron | FE3 MEDICAL, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140374104-A1 | COMPOSITION AND METHOD FOR TREATING OILFIELD WATER | BAKER HUGHES INCORPORATED (US) | 2014-12-25 | — | — | US | disclosed |
| US-8821945-B2 | Method for transdermal iontophoretic delivery of chelated agents | FE3 MEDICAL, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8802114-B2 | Pharmaceutical compositions of iron for oral administration | MERRION RESEARCH III LIMITED (IE) | 2014-08-12 | — | — | US | disclosed |
| US-20140134290-A1 | ANIMAL FEED ADDITIVES | Inco Digestive, Inc. (US) | 2014-05-15 | — | — | US | disclosed |
| EP-2709714-A1 | APPARATUS AND METHOD FOR HEATING A TREATMENT REGION WITH AN ALTERNATING ELECTRIC FIELD | Innovolink, LLC (US) | 2014-03-26 | — | — | EP | disclosed |
| US-20130341281-A1 | Surface Modified Ceramic Filter | UNIVERSITY OF KANSAS (US) | 2013-12-26 | — | — | US | disclosed |
| CN-103476419-A | Pharmaceutical compositions of iron for oral administration | MERRION RES III LTD | 2013-12-25 | — | — | CN | disclosed |
| EP-2661273-A2 | PHARMACEUTICAL COMPOSITIONS OF IRON FOR ORAL ADMINISTRATION | Merrion Research III Limited (IE) | 2013-11-13 | — | — | EP | disclosed |
| US-20130189374-A1 | METHODS AND COMPOSITIONS FOR ENHANCING IRON ABSORPTION | DRUGTECH CORPORATION (US) | 2013-07-25 | — | — | US | disclosed |
| WO-2013075018-A1 | SURFACE MODIFIED CERAMIC FILTER | UNIVERSITY OF KANSAS (US) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013012657-A1 | ANIMAL FEED ADDITIVES | INCO DIGESTIVE, LLC (US) | 2013-01-24 | — | — | WO | disclosed |
| US-20130022706-A1 | Animal Feed Additive | INCO DIGESTIVE, LLC (US) | 2013-01-24 | — | — | US | disclosed |
| WO-2012154736-A1 | APPARATUS AND METHOD FOR HEATING A TREATMENT REGION WITH AN ALTERNATING ELECTRIC FIELD | INNOVOLINK, LLC (US) | 2012-11-15 | — | — | WO | disclosed |
| US-20120289955-A1 | Apparatus and Method for Heating Biological Targets | INNOVOLINK, LLC | 2012-11-15 | — | — | US | disclosed |
| US-20120290049-A1 | Apparatus and Method for Providing a Substantially Constant Voltage Between Electrodes Extending Across a Treatment Region | INNOVOLINK, LLC | 2012-11-15 | — | — | US | disclosed |
| US-20120290050-A1 | Apparatus and Method for Obtaining a Substantially Constant Current Across a Treatment Region | INNOVOLINK, LLC | 2012-11-15 | — | — | US | disclosed |
| US-20120289956-A1 | Apparatus and Method for Heating Adipose Cells | INNOVOLINK, LLC | 2012-11-15 | — | — | US | disclosed |
| US-20120290048-A1 | Apparatus and Method for Heating a Treatment Region with an Alternating Electric Field | INNOVOLINK, LLC | 2012-11-15 | — | — | US | disclosed |
| US-20120189692-A1 | Pharmaceutical Compositions of Iron for Oral Administration | NOVO NORDISK A/S (DK) | 2012-07-26 | — | — | US | disclosed |
| US-20120184894-A1 | Patches and Methods for the Transdermal Delivery of Agents to Treat Hair Loss | INCUBE LABS, LLC | 2012-07-19 | — | — | US | disclosed |
| US-20120177700-A1 | Nanonized Iron Compositions and Methods of Use Thereof | FE3 MEDICAL, INC. | 2012-07-12 | — | — | US | disclosed |
| WO-2012094598-A2 | PHARMACEUTICAL COMPOSITIONS OF IRON FOR ORAL ADMINISTRATION | MERRION RESEARCH III LIMITED (IE) | 2012-07-12 | — | — | WO | disclosed |
| WO-2012092305-A2 | NANONIZED IRON COMPOSITIONS AND METHODS OF USE THEREOF | INCUBE LABS, LLC (US) | 2012-07-05 | — | — | WO | disclosed |
| WO-2012092628-A2 | PATCHES AND METHODS FOR THE TRANSDERMAL DELIVERY OF AGENTS TO TREAT HAIR LOSS | INCUBE LABS, LLC (US) | 2012-07-05 | — | — | WO | disclosed |
| EP-2421601-A2 | METHOD FOR TRANSDERMAL IONTOPHORETIC DELIVERY OF CHELATED AGENTS | Incube Labs, Llc (US) | 2012-02-29 | — | — | EP | disclosed |
| US-8080520-B2 | Composition and method for treating iron deficiency anemia | NURYA BRANDS, INC. | 2011-12-20 | — | — | US | disclosed |
| EP-2320885-A1 | PATCHES AND METHODS FOR THE TRANSDERMAL DELIVERY OF A THERAPEUTICALLY EFFECTIVE AMOUNT OF IRON | Fe3 Medical, Inc (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2009158032-A9 | PATCHES AND METHODS FOR THE TRANSDERMAL DELIVERY OF A THERAPEUTICALLY EFFECTIVE AMOUNT OF IRON | FE3 MEDICAL, INC (US) | 2011-03-03 | — | — | WO | disclosed |
| US-20110015150-A1 | METHODS OF ADMINISTERING COMPOSITIONS INCLUDING IRON | DRUGTECH CORPORATION (US) | 2011-01-20 | — | — | US | disclosed |
| WO-2010123584-A2 | METHOD FOR TRANSDERMAL IONTOPHORETIC DELIVERY OF CHELATED AGENTS | INCUBE LABS, LLC (US) | 2010-10-28 | — | — | WO | disclosed |
| US-20100130912-A1 | Patches and methods for the transdermal delivery of a therapeutically effective amount of iron | FE2, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100129496-A1 | NUTRITIONAL FORMULATIONS | DRUGTECH CORPORATION (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130910-A1 | Patches and method for the transdermal delivery of a therapeutically effective amount of iron | FE2, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100112676-A1 | ODOR CONTROL METHODS AND COMPOSITIONS | COATES JOHN D | 2010-05-06 | — | — | US | disclosed |
| WO-2009158032-A1 | PATCHES AND METHODS FOR THE TRANSDERMAL DELIVERY OF A THERAPEUTICALLY EFFECTIVE AMOUNT OF IRON | FE2, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| US-20090281021-A1 | Composition and Method for Treating Iron Deficiency Anemia | NURYA BRANDS, INC. | 2009-11-12 | — | — | US | disclosed |
| US-7585527-B2 | Composition and method for treating iron deficiency anemia | NURYA BRANDS, INC. | 2009-09-08 | — | — | US | disclosed |
| WO-2009032699-A1 | ANTI-PROLIFERATIVE COMBINATIONS | DRUGTECH CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| US-20090068190-A1 | ANTI-PROLIFERATIVE COMBINATIONS | DRUGTECH CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090035385-A1 | COMPOSITIONS INCLUDING IRON | DRUGTECH CORPORATION (US) | 2009-02-05 | — | — | US | disclosed |
| US-20090028962-A1 | Methods and Compositions for Enhancing Iron Absorption | DRUGTECH CORPORATION (US) | 2009-01-29 | — | — | US | disclosed |
| EP-1750682-A4 | NUTRITIONAL FORMULATIONS | DRUGTECH CORP (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2008100767-A1 | COMPOSITIONS FOR IMPROVING GASTROINTESTINAL NUTRIENT AND DRUG ABSORPTION | DRUGTECH CORPORATION (US) | 2008-08-21 | — | — | WO | disclosed |
| US-20080193531-A1 | COMPOSITIONS FOR IMPROVING GASTROINTESTINAL NUTRIENT AND DRUG ABSORPTION | DRUGTECH CORPORATION (US) | 2008-08-14 | — | — | US | disclosed |
| EP-1827418-A2 | COMPOSITIONS INCLUDING IRON | Drugtech Corporation (US) | 2007-09-05 | — | — | EP | disclosed |
| EP-1827419-A2 | METHODS AND COMPOSITIONS FOR ENHANCING IRON ABSORPTION | Drugtech Corporation (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2007035757-A2 | COMPOSITION AND METHOD FOR TREATING IRON DEFICIENCY ANEMIA | VENKATARAMAN BALA (US) | 2007-03-29 | — | — | WO | disclosed |
| US-20070065521-A1 | Composition and method for treating iron deficiency anemia | NURYA BRANDS, INC. | 2007-03-22 | — | — | US | disclosed |
| US-20070059815-A1 | Odor control methods and compositions | BOARD OF TRUSTEES AT SOUTHERN ILLINOIS UNIVERSITY | 2007-03-15 | — | — | US | disclosed |
| EP-1750682-A2 | NUTRITIONAL FORMULATIONS | Drugtech Corporation (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2006068697-A2 | COMPOSITIONS INCLUDING IRON | DRUGTECH CORPORATION (US) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006068729-A2 | METHODS AND COMPOSITIONS FOR ENHANCING IRON ABSORPTION | DRUGTECH CORPORATION (US) | 2006-06-29 | — | — | WO | disclosed |
| US-20060134227-A1 | Compositions including iron | DRUGTECH CORPORATION | 2006-06-22 | — | — | US | disclosed |
| WO-2005120524-A2 | NUTRITIONAL FORMULATIONS | DRUGTECH CORPORATION (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050037065-A1 | NUTRITIONAL FORMULATIONS | DRUGTECH CORPORATION (US) | 2005-02-17 | — | — | US | disclosed |
| WO-2003086321-A2 | MODIFIED RELEASE MINERALS | DRUGTECH CORPORATION (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20030190355-A1 | Modified release minerals | DRUGTECH CORPORATION | 2003-10-09 | — | — | US | disclosed |
| EP-0299942-B1 | ANTIFREEZE COMPOSITION | NIPPON SHOKUBAI CO., LTD. (JP) | 1992-12-02 | — | — | EP | disclosed |
| US-5080818-A | Antifreeze composition | NIPPON SHOKUBAI KAGAKU KOGYO CO., LTD. (JP) | 1992-01-14 | — | — | US | disclosed |
| EP-0299942-A2 | Antifreeze composition | NIPPON SHOKUBAI CO., LTD. (JP) | 1989-01-18 | — | — | EP | disclosed |
| EP-0299942-A2 | Antifreeze composition | NIPPON SHOKUBAI CO., LTD. (JP) | 1989-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189447-A1 | FORMULATION FOR INCREASING ENERGY | COQ8A, COQ8B, NDUFS6 | CA4 3260/4885ALDH1A1 2945/4885CASP1 4425/4885 |
| US-20090068190-A1 | ANTI-PROLIFERATIVE COMBINATIONS | FOLR2, FOLR1, DHFR | CA4 3988/4885ALDH1A1 1172/4885CASP1 1282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.